Beginning this week, pharmaceutical executives will be on the spot as they reveal their companies’ earnings for the first time since major drug pricing legislation was enacted in the U.S.
The law was a significant defeat for the industry, but its impact will be varied, hitting some drugmakers harder than others when its central provision first takes effect in 2026. Analysts are likely to quiz company CEOs on how the law affects their sales forecasts, as well as their research and development plans.
